Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Retained Earnings (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Retained Earnings data on record, last reported at -$1.2 billion in Q4 2025.

  • For Q4 2025, Retained Earnings fell 29.84% year-over-year to -$1.2 billion; the TTM value through Dec 2025 reached -$1.2 billion, down 29.84%, while the annual FY2025 figure was -$1.2 billion, 29.84% down from the prior year.
  • Retained Earnings reached -$1.2 billion in Q4 2025 per OCUL's latest filing, down from -$1.1 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$536.1 million in Q1 2021 and bottomed at -$1.2 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$736.6 million, with a median of -$668.1 million recorded in 2023.
  • The widest YoY moves for Retained Earnings: up 1.22% in 2021, down 32.34% in 2021.
  • A 5-year view of Retained Earnings shows it stood at -$545.8 million in 2021, then dropped by 13.02% to -$616.8 million in 2022, then dropped by 13.09% to -$697.6 million in 2023, then dropped by 27.74% to -$891.1 million in 2024, then decreased by 29.84% to -$1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.2 billion in Q4 2025, -$1.1 billion in Q3 2025, and -$1.0 billion in Q2 2025.